Loading...
Market
Biogen's primary acquisition target type in 2025
2
Chris Viehbacher•JPMorgan Healthcare Conference•San Francisco•Viehbacher•Biogen•Sage Therapeutics•Zurzuvae•Sage
Resolution / Starting Odds
Sage Therapeutics • 25%
A company with mid-stage drug development • 25%
A company with late-stage drug development • 25%
A company with a marketed drug • 25%
Official press releases from Biogen, major financial news outlets
Story
Biogen CEO Confirms Intent to Acquire Biotechs, Including $469 Million Offer for Sage Therapeutics
Jan 12, 2025, 04:01 PM
Biogen Inc. is actively seeking to expand its portfolio through acquisitions in the biotech sector, as confirmed by CEO Chris Viehbacher at the JPMorgan Healthcare Conference in San Francisco. Viehbacher expressed Biogen's intent to engage in deals, though he did not specify the size of these potential acquisitions. This comes after Biogen's recent $469 million offer to acquire Sage Therapeutics, its partner in marketing Zurzuvae, a pill for postpartum depression. The offer, which is less than Sage's current cash reserves, is unlikely to be accepted due to Sage's recent clinical failures and stock price decline. Biogen's strategy is to target biotechs with drugs in mid- and late-stage clinical development to augment its growth.
View original story
Similar markets
Another named biotech company • 25%
No further acquisitions • 25%
Multiple companies • 25%
Stoke Therapeutics • 25%
Gilead Sciences • 25%
Biogen • 25%
Vertex Pharmaceuticals • 25%
Other Biopharma Companies • 25%
Other • 25%
Johnson & Johnson • 25%
Eli Lilly • 25%
GSK • 25%
Eli Lilly • 25%
GSK • 25%
Pfizer • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Other • 25%
AstraZeneca • 25%
Gilead Sciences • 25%
Biogen • 25%
Acquisition completed at proposed price • 25%
Acquisition completed at a different price • 25%
Acquisition not completed • 25%
Acquisition rejected • 25%
Infectious diseases • 25%
Cancer • 25%
Neurological disorders • 25%
Other • 25%
None • 25%
CEO • 25%
CTO • 25%
CFO • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Focus on genetic engineering • 25%
Focus on cancer treatments • 25%
Focus on other areas • 25%
Focus on both equally • 25%